Nexentis Technologies Inc, formerly known as N2OFF, Inc., is an AI and data-driven computational biotech platform focused on mitochondrial biology, precision oncology and inflammatory metabolic diseases. Through its subsidiary MitoCareX Bio Ltd. The company uses a proprietary discovery engine targeting the mitochondrial SLC25 carrier family using its MITOLINE algorithm and structure guided virtual screening workflows. MITOLINE, its proprietary computational platform, is designed to allow proper homology modeling of mitochondrial membrane proteins, particularly transport proteins. It enables three-dimensional structural modeling and large-scale virtual screening, MITOLINE opens access to a novel untapped target space, allowing the Company to identify small-molecule modulators that directly disrupt cancer metabolism with the potential of minimizing systemic toxicity.
Back to dashboard
Company Information
About this company
Key people
Amitay Weiss
Independent Chairman of the Board
David Palach
Chief Executive Officer
Lital Barda
Chief Financial Officer
Dan Sztybel
Chief Executive Officer of Save Foods Ltd.
Shlomo Zakai
Chief Financial Officer, Controller
Asaf Itzhaik
Director
Liat Sidi
Director
Eliahou Arbib
Independent Director
Israel Berenstein
Independent Director
Click to see more
Key facts
- Shares in issue1.45m
- EPICNXTS
- ISINUS80512Q6008
- LocationIsrael
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$937,550.00
- Employees7
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.